Anika Therapeutics | ANIK - Ordinary Share Capital


Anika Therapeutics reported $13.89M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
Abbott USD 1.74B 23.39B Sep/2025
Agenus USD 35.32M 2.51M Dec/2025
Agios Pharmaceuticals USD 59.34M 892K Mar/2026
Anika Therapeutics USD 13.89M 532K Dec/2025
Arrowhead Research USD 137.39M 1.69M Dec/2025
Enanta Pharmaceuticals USD 212K 1000 Dec/2023
Halozyme Therapeutics USD 118.52M 741K Mar/2026
Heron Therapeutics USD 188.31M 4.99M Dec/2025
Insmed USD 216.52M 2.27M Mar/2026
Integra LifeSciences USD 77.82M 69K Mar/2026
Intrexon USD 0 0 Jun/2024
J&J USD 2.41B 1.74M Dec/2025
Karyopharm Therapeutics USD 18.31M 18.3M Dec/2025
Ligand Pharmaceuticals USD 19.66M 19.64M Sep/2025
MacroGenics USD 63.56M 241K Mar/2026
Merit Medical Systems USD 59.65M 231K Mar/2026
Rigel Pharmaceuticals USD 17K 158K Jun/2024
Sanofi EUR 1.21B 8.25M Mar/2026
Smith & Nephew USD 875.96M 1.61M Dec/2025
Stryker USD 382.98M 584K Mar/2026
Veracyte USD 79.79M 743K Mar/2026
Xencor USD 74.06M 2.19M Mar/2026
Zimmer Biomet Holdings USD 195.5M 2.68M Mar/2026